Retatrutide for Beginners: Everything You Need to Know

Retatrutide is the most exciting weight loss drug in development. If you are just hearing about it for the first time, here is what you need to know: retatrutide is an investigational injectable medication from Eli Lilly that produced an average of 24.2% body weight loss in clinical trials — roughly 71 pounds for the average participant (Jastreboff et al., NEJM 2023). It works by activating three hormone receptors simultaneously, making it the most effective pharmaceutical weight loss treatment ever tested. This guide breaks everything down in plain language.

What Is Retatrutide?

In simple terms, retatrutide is a weight loss shot you take once a week. It belongs to the same family of medications as Ozempic and Mounjaro, but it is more powerful because it targets three hormone pathways instead of one or two.

Here is the quick comparison:

• Ozempic/Wegovy (semaglutide): Targets 1 receptor (GLP-1). Average weight loss: 15-17%.
• Mounjaro/Zepbound (tirzepatide): Targets 2 receptors (GLP-1 + GIP). Average weight loss: 20-22%.
• Retatrutide: Targets 3 receptors (GLP-1 + GIP + Glucagon). Average weight loss: 24.2%.

Each additional receptor adds a new way to fight obesity. More pathways means more weight loss.

How Does It Work? (Simple Version)

Your body has hormones that control hunger, metabolism, and fat storage. Retatrutide mimics three of these hormones at once:

Think of it this way: GLP-1 and GIP reduce the calories going in (by cutting appetite). Glucagon increases the calories going out (by burning more fat). Retatrutide attacks obesity from both directions at once.

What Did the Clinical Trials Show?

The Phase 2 trial results, published in the New England Journal of Medicine in 2023, were remarkable:

• Average weight loss: 24.2% of body weight at the highest dose (12 mg)
• In pounds: Approximately 71 pounds for the average participant
• Percentage who lost 15%+: 83% of participants
• Percentage who lost 25%+: 54% of participants
• Still losing at study end: The weight loss curve had not plateaued at 48 weeks
• Liver fat: Up to 86% reduction in liver fat content

These numbers are unprecedented for any pharmaceutical weight loss treatment. More than half of participants on the highest dose lost more than a quarter of their body weight — results that approach bariatric surgery.

What Are the Side Effects?

Retatrutide's side effects are similar to other medications in this class. The most common ones are digestive:

• Nausea: The most common side effect, especially during the first few weeks and after dose increases. Usually mild to moderate.
• Diarrhea: Occurs in some patients, typically during dose escalation.
• Vomiting: Less common than nausea, but possible during adjustment periods.
• Constipation: Some patients experience constipation rather than diarrhea.
• Decreased appetite: This is actually the intended effect, but some people find it more pronounced than expected.

These side effects tend to be worst during the initial dose escalation period and improve as your body adjusts. The gradual dose escalation protocol is specifically designed to minimize these issues.

When Will It Be Available?

Here is the expected timeline:

• Now (2026): Phase 3 clinical trials (the TRIUMPH program) are ongoing
• 2026-2027: Phase 3 results expected to be reported
• 2027 (estimated): Potential FDA approval if trials succeed
• Post-approval: Gradual insurance coverage rollout

Important caveat: these timelines are estimates. Drug development is unpredictable, and delays are common. The FDA approval timeline depends on trial results, regulatory review speed, and manufacturing readiness.

How Much Will It Cost?

Pricing has not been announced, but based on comparable medications:

• Wegovy (semaglutide) lists at ~$1,350/month
• Zepbound (tirzepatide) lists at ~$1,060/month
• Retatrutide will likely fall in a similar or higher range initially

For more details on expected pricing, see our retatrutide cost analysis.

What Can You Do Right Now?

You do not have to wait for retatrutide to start your weight loss journey. The medications available today are highly effective:

• Compounded semaglutide: $99/month through TRIMI — same active ingredient as Ozempic/Wegovy, producing 15-17% average weight loss
• Compounded tirzepatide: $125/month through TRIMI — same active ingredient as Mounjaro/Zepbound, producing 20-22% average weight loss

Starting now gives you immediate health benefits. And if retatrutide is approved later, you can discuss transitioning with your provider. Think of current medications as your launchpad, not your ceiling.

Learn more about how TRIMI works — from online consultation to medication delivery.